Mostrar o rexistro simple do ítem

dc.contributor.authorRoldán Rabadán, Inmaculada
dc.contributor.authorEsteve-Pastor, María Asunción
dc.contributor.authorAnguita, Manuel
dc.contributor.authorMuñiz, Javier
dc.contributor.authorRuiz Ortiz, Martín
dc.contributor.authorMarín, Francisco
dc.contributor.authorRoldán, Vanessa
dc.contributor.authorQuesada, María Angustias
dc.contributor.authorCamacho Siles, José
dc.contributor.authorCequier Fillat, Angel
dc.contributor.authorBertomeu-Martínez, Vicente
dc.contributor.authorMartínez-Sellés, Manuel
dc.contributor.authorBadimón, Lina
dc.date.accessioned2020-06-02T09:45:09Z
dc.date.issued2020-04-14
dc.identifier.citationRoldán Rabadán I, Esteve-Pastor MA, Anguita Sánchez M, Muñiz J, Ruiz Ortiz M, Marín F, Roldán V, Quesada MA, Camacho Siles J, Cequier Fillat A, Bertomeu Martinez V, Martínez Sellés M, Badimón L; FANTASIIA Study Investigators. Influence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIIA study. Eur J Intern Med. 2020 Aug;78:63-68.es_ES
dc.identifier.issn1879-0828
dc.identifier.urihttp://hdl.handle.net/2183/25677
dc.description.abstract[Abstract] Background: While many risk factors for Atrial Fibrillation (AF) have been identified, there are important differences in their relative impact between sexes. The aim of our study was to investigate the influence of sex as a long-term predictor of adverse events in “real world” AF patients treated with direct oral anticoagulants. Methods: The FANTASIIA registry is a prospective, national and multicentric study including outpatients with anticoagulated AF patients. Baseline characteristics and adverse events at 3 years of follow-up were collected and classified by sex. Cox multivariate analysis was performed to investigate the role of sex in major events and composite outcomes. Results: A total of 1956 patients were included in the study. 43.9% of them were women, with a mean age of 73.8 ± 9.4 years (women were older 76.5 ± 7.9 vs 71.7 ± 10.1, p<0.001). Women had higher rate of cardiovascular risk factors and higher mean of CHA2DS2-VASc (4.4 ± 1.4 vs 3.7 ± 1.6, p<0.001) and HAS-BLED (2.1 ± 1.0 vs 1.9 ± 1.1, p<0.001) than men. After 3 years of follow-up, rates of major events were similar in both groups with limit difference for all-cause mortality (4.4%/year in women vs 5.6%/year in men; p = 0.056). However, all the composite events were more frequent in women. We observed in the non-adjusted adverse events lower rate of all-cause mortality (HR 0.62, 95%CI 0.47–0.81; p<0.001), composite 1 outcomes (HR 0.80, 95%CI 0.65–0.98; p = 0.029) and composite 2 (HR 0.77, 95%CI 0.64–0.94; p = 0.010) in women compared with men. In multivariate Cox regression analysis observed that female sex was an independently protector factor for all-cause mortality and for the composite outcomes 1 and 2. Conclusions: In this “real world” study of anticoagulated AF patients, women could have a protective role against development of adverse events, mainly on all-cause mortality and combined events.es_ES
dc.description.sponsorshipThe FANTASIIA registry was funded by an unconditional grant from Pfizer/Bristol-Myers-Squibb and by grants from the Instituto de Salud Carlos III (Madrid)-FEDER (RD12/0042/0068, RD12/0042/0010, RD12/0042/0069 and RD12/0042/0063).es_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Acción Estratégica de Salud/RD12%2F0042%2F0068/ES/Enfermedades cardiovasculareses_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Acción Estratégica de Salud/RD12%2F0042%2F0010/ES/Enfermedades cardiovasculareses_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Acción Estratégica de Salud/RD12%2F0042%2F0069/Enfermedades cardiovasculareses_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/MINECO/Acción Estratégica de Salud/RD12%2F0042%2F0063/ES/Enfermedades cardiovasculares
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.urihttps://doi.org/10.1016/j.ejim.2020.04.012es_ES
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC-BY-NC-ND 4.0)es_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0*
dc.subjectAtrial fibrillationes_ES
dc.subjectRole of sexes_ES
dc.subjectDirect oral anticoagulantses_ES
dc.subjectVitamin K antagonistses_ES
dc.subjectFANTASIIA registryes_ES
dc.titleInfluence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIIA studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/embargoedAccesses_ES
dc.date.embargoEndDate2021-04-14es_ES
dc.date.embargoLift2021-04-14
UDC.journalTitleEuropean Journal of Internal Medicinees_ES


Ficheiros no ítem

Thumbnail
Thumbnail
Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem